Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects

• Published in: Neurological research (New York) Vol. 34; no. 7; p. 669
• Main Authors: Maarouf, Chera L, Beach, Thomas G, Adler, Charles H, Shill, Holly A, Sabbagh, Marwan N, Wu, Terence, Walker, Douglas G, Kokjohn, Tyler A, Roher, Alex E
• Format: Journal Article
• Language: English
• Published: England 01.09.2012
• Subjects: Aged; Aged, 80 and over; Apolipoprotein A-I - cerebrospinal fluid; Apolipoproteins E - cerebrospinal fluid; Biomarkers - cerebrospinal fluid; Clusterin - cerebrospinal fluid; Cohort Studies; Female; Fibrinogen - cerebrospinal fluid; Glutathione S-Transferase pi - cerebrospinal fluid; Humans; Male; Middle Aged; Parkinson Disease - cerebrospinal fluid; Parkinson Disease - diagnosis; Parkinson Disease - pathology; Prealbumin - cerebrospinal fluid; Protein Isoforms - cerebrospinal fluid; Two-Dimensional Difference Gel Electrophoresis - methods
• ISSN: 1743-1328
• DOI: 10.1179/1743132812Y.0000000063

Parkinson's disease (PD) afflicts approximately 1-2% of the population over 50 years of age. No cures or effective modifying treatments exist and clinical diagnosis is currently confounded by a lack of definitive biomarkers. We sought to discover potential biomarkers in the cerebrospinal fluid (CSF) of neuropathologically confirmed PD cases. We compared postmortem ventricular CSF (V-CSF) from PD and normal control (NC) subjects using two-dimensional difference gel electrophoresis (2D-DIGE). Spots exhibiting a 1·5-fold or greater difference in volume between PD patients and controls were excised from the two-dimensional gels, subjected to tryptic digestion and identification of peptides assigned using mass spectrometric/data bank correlation methods. Employing this strategy six molecules: fibrinogen, transthyretin, apolipoprotein E, clusterin, apolipoprotein A-1, and glutathione-S-transferase-Pi, were found to be different between PD and NC populations. These molecules have been implicated in PD pathogenesis. Combining biomarker data from multiple laboratories may create a consensus panel of proteins that may serve as a diagnostic tool for this neurodegenerative disorder.